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Introduction: Fiducial markers act as visible surrogates of tumor 
position during image-guided radiotherapy. Marker placement has 
been attempted percutaneously but is associated with high rates of 
pneumothorax and chest drain placement.
Methods: Patients undergoing radical radiation treatment for non–
small-cell lung cancer underwent bronchoscopic implantation of 
gold fiducials using radial probe endobronchial ultrasound (EBUS) 
with virtual bronchoscopy and fluoroscopic guidance to achieve 
tumor localization and placement within/adjacent to peripheral lung 
tumors. For tumors not localized using radial EBUS, fiducial place-
ment was achieved by electromagnetic navigation to the vicinity of 
the tumor.
Results: Eighteen fiducials were placed to mark 16 lesions in 15 
patients. In nine patients (60%), fiducials were implanted at the time 
of diagnostic bronchoscopy. No procedural complications occurred. 
EBUS localization allowed marker implantation within the target 
lesion in 12 cases. In four lesions, electromagnetic navigation bron-
choscopy-guided implantation achieved a median fiducial–lesion 
distance of 6 mm (mean 12 mm). No marker migration occurred after 
the implantation of two-band markers; however, early migration was 
observed in two of eight (25%) of the smaller linear fiducials. No 
migration during the course of radiation therapy was observed.
Conclusion: Fiducial marker placement is easily and safely per-
formed bronchoscopically, including at the time of diagnostic 
bronchoscopy. Marker geometry appears important in stability of 
bronchoscopically inserted fiducials. Future studies are required to 
confirm the optimal marker size, geometry, and spatial relationship 
with the target lesion.
Key Words: Stereotactic radiotherapy, Lung cancer, Endobronchial 
ultrasound.
(J Thorac Oncol. 2015;10: 324–330)
Fiducial markers are frequently used in management of pulmonary lesions to either aid localization of pulmonary 
lesions during minimally invasive surgery,1,2 or precisely iden-
tify the location of pulmonary lesions being targeted with 
external beam radiotherapy.3 Failure to locate small nodules 
at thoracoscopic surgery may result in incomplete resection 
or conversion to open thoracotomy. Peripheral lung tumors 
may demonstrate significant respiratory-induced motion, with 
large variations in magnitude and direction from patient to 
patient, fraction to fraction, and importantly, cycle to cycle.4 
The ensuing suboptimal targeting of radiation can result in 
excess toxicity and geographic tumor miss. There has par-
ticularly been an increasing interest in fiducial markers for 
image guidance for stereotactic ablative body radiotherapy.5,6 
Markers allowing reliable and accurate determination of lung 
lesion position have the potential to significantly improve 
treatment safety and outcomes.
Marker insertion through a percutaneous route has been 
associated with a high rate of complications.7–9 Bronchoscopic 
placement is feasible but requires guidance tools to achieve 
accurate localization as lesions are not visible at bronchos-
copy. Previous reports suggest that electromagnetic naviga-
tion guidance may allow marker placement in the vicinity 
of parenchymal lesions10,11 though accuracy of placement 
remains poorly described. Only one previous study has uti-
lized endobronchial ultrasound (EBUS), with electromagnetic 
navigation bronchoscopy (ENB) in selected cases, to guide 
marker placement. The authors reported a high degree of 
accuracy using the combination of guidance tools, though the 
exact contribution of each modality to accuracy is unclear.12 
The optimal methods to aid bronchoscopic marker implanta-
tion therefore remain uncertain, and no examination of marker 
features (size, shape, geometry) have been published.
Our institution utilizes numerous techniques to aid 
bronchoscopic localization of peripheral pulmonary lesions, 
including radial EBUS, virtual bronchoscopy (VB), and 
ENB. We have used fiducial markers to localize small pulmo-
nary nodules, with a sequential approach to use of broncho-
scopic techniques. In this report, we describe our preliminary 
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experience in implantation of two different types of lung 
fiducial markers and present our experience regarding the 
components of bronchoscopic fiducial marker placement and 
describe our preliminary experience in implantation of two 
different types of lung fiducial markers.
PATIENTS AND METHODS
Institutional review board approval was granted for per-
formance of this prospective observational study. All patients 
provided written informed consent.
Consecutive patients referred for bronchoscopic fiducial 
marker placement were selected on the basis of the following:
 1.  Confirmed early stage peripheral lung malignancy in 
patients deemed medically inoperable, where fiducial 
marker placement was performed to aid external beam 
tumor irradiation, and
 2.  Presumed/confirmed pulmonary metastases, where 
marker placement was performed to aid stereotactic abla-
tive body radiotherapy or to aid thoracoscopic resection 
of pulmonary metastases.
Bronchoscopic Localization of Target Lesion
Bronchoscopy was performed with a standard videobron-
choscope (BF-MP160F or BF-P180; Olympus, Tokyo, Japan) 
under conscious sedation as previously described.13 Guidance 
tools to ensure accurate marker placement were utilized in 
as “sequential” fashion, with VB planning and radial EBUS 
(described below) used to locate the target lesion in all patients. 
In patients where lesion position could not be confirmed by 
EBUS, within the same procedure ENB was used to identify 
the position within the bronchial tree closest to the target lesion.
Randomized trials have indicated VB significantly 
improves localization of small peripheral lesions.14 We 
therefore completed VB preprocedure planning using mul-
tiplanar formatting of Digital Imaging and Communications 
in Medicine (DICOM) data from computed tomography 
(CT) chest (slice thickness 1.0 mm with 0.8 mm overlap). 
Three-dimensional reconstruction of the bronchial tree 
from DICOM images was performed using iLogic software 
(SuperDimension Inc., Plymouth, MN). A bronchoscopic 
pathway was determined using the iLogic software and local-
ization of lesions was first attempted using radial EBUS as 
previously described,13 based on the “virtual bronchoscopy” 
pathway.
If EBUS findings indicated successful localization of 
the lesion, the radial EBUS probe was removed, with the guide 
sheath remaining in situ. For lesions where preprocedure tis-
sue diagnosis was known, we proceeded to placement of the 
fiducial marker. In patients where tissue diagnosis was uncon-
firmed, bronchial brushings from the lesion were performed 
and subject to rapid on-site cytologic evaluation.15 Only when 
brushings confirmed the presence of diagnostic malignant 
material was placement of fiducial marker performed.
In patients where radial EBUS was unable to con-
firm the location of the target lesion, we proceeded to ENB 
(inReach system, SuperDimension Ltd, Minneapolis, MN). 
Performance of this technique has been described in detail 
previously.16 Briefly, bronchoscopic direction was controlled 
using a steerable locator guide emits low frequency electro-
magnetic waves. Electromagnetic signal is detected by an elec-
tromagnetic location board which lies underneath the patient. 
The position of the probe within the bronchial tree is localized 
within a virtual bronchoscopic tree which is constructed by the 
iLogic software from the DICOM images, as described above. 
Navigation to the lesion location is undertaken and the mini-
mum average fiducial target registration error (AFTRE) was 
recorded. The locator guide was withdrawn from an extended 
working channel (EWC) and repeat EBUS examination was 
performed. Subsequently, sampling (brushings, TBLB, wash-
ings) was performed under fluoroscopic vision.
Marker Placement
Markers used were determined by marker availabil-
ity. Markers were either a linear fiducial 10 × 0.75 mm lin-
ear marker (Visicoil; Robertson Medical, Coffs Harbour, 
Australia), or a two-band 13 × 0.9 mm marker (superLock; 
SuperDimension Ltd, Minneapolis, MN) (Fig. 1).
Before the removal of the radial EBUS probe, or steer-
able locator guide, fluoroscopic imaging was used to determine 
the location of the lesion within the lung fields. Markers were 
then inserted into the guide sheath (EBUS-located lesions) or 
EWC (ENB procedures) and advanced to the tip of the sheath 
using sampling instruments. Insertion was performed under 
fluoroscopic vision to ensure that the location was the same as 
where the lesion had been located.
Postprocedure Imaging
Patients underwent chest x-ray (CXR) within 2 hours 
of their procedure to confirm marker position and retention. 
More detailed imaging was performed with 4D planning CT 
7 to 12 days postprocedure. This study confirmed the posi-
tioning of the marker relative to the target lesion (marker 
accuracy). Confirmation of retention of the marker (marker 
stability) was also noted at this study. Subsequent imaging 
was performed according to clinical need.
The positioning of the marker relative to the target 
lesion (marker accuracy) was established was bas based on 
imaging obtained at the 4D planning CT. 
RESULTS
From September 26, 2012 to February 19, 2014, 18 
fiducials were placed bronchoscopically to mark 16 lesions 
FIGURE 1.  Fiducial markers used. A, 10 × 0.75 mm linear 
marker and (B) two-band 13 × 0.9 mm marker.
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in 15 patients. One lesion was marked by two fiducials, and 
one lesion was subjected to a second marker placement pro-
cedure as, after the initial ENB-directed placement, lesion–
marker distance was thought to be too great to adequately aid 
external beam irradiation (see Supplementary Video file 1, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A730). No procedural complications occurred. Clinical sce-
nario and procedural outcomes are recorded in Table 1.
The indications for placement of fiducial markers were 
for guidance of external beam irradiation in 14 patients (15 
lesions), and to aid surgical resection of a presumed pulmo-
nary metastasis in one patient. Only three patients had a con-
firmed tissue diagnosis before marker placement. A further 
four lesions were presumed metastatic on the basis of prior 
history of carcinoma and observed growth of pulmonary nod-
ules. The remaining nine lesions underwent placement at the 
time of diagnostic bronchoscopy, with on-site cytology exami-
nation of bronchial brushings indicating malignancy, and final 
pathology examination confirming non–small-cell lung can-
cer in all 10 lesions.
Marker Accuracy
EBUS successfully located 12 of the target lesions, 
allowing marker placement within the target lesion (Fig. 2). 
In the remaining four lesions, ENB was used to guide place-
ment with a median and mean intraprocedure AFTRE of 8 mm. 
Postprocedure planning CT indicated a median marker–lesion 
distance of 6 mm (mean 12 mm), but with one lesion show-
ing significant marker–lesion discrepancy of 35 mm despite an 
intraprocedural AFTRE of 9 mm. This patient underwent repeat 
EMN-guided marker placement through a different lobar sub-
segment and achieved a marker–lesion distance of 4 mm.
Marker Stability
No marker migration was observed after the insertion of 
the two-band markers. Early marker migration was observed 
in two of eight patients (25%) in whom Visicoil markers 
were placed. One marker was presumed expectorated as it 
was not seen on imaging at day 10 postimplantation despite 
being observed in situ on CXR performed day 2 postim-
plantation. The marker was placed within a cavitating lesion 
65 mm from a lobar bronchus. The other marker was noted to 
have migrated down toward the lung base after the placement 
within the lesion only 14 mm from the lobar bronchus. It was 
subsequently visualized at the diaphragmatic pleura (Fig. 3) 
on imaging performed day 1 postprocedure.
DISCUSSION
Our experience confirms that bronchoscopic inser-
tion of fiducial markers for localization of peripheral lung 
lesions is accurate and safe and demonstrates that EBUS is 
able to target marker placement with excellent marker accu-
racy. Advantages of bronchoscopic insertion are the ability to 
perform diagnostic biopsy and marker placement in the one 
procedure, the excellent safety profile of bronchoscopy, pro-
cedural cost minimization, and the ability of radial EBUS to 
confirm localization of the tumor and enable highly accurate 
placement of markers within lesions of interest. Our rate of 
intratumor localization (75%), achieved using EBUS, is supe-
rior to the rate previously reported for percutaneous fiducial 
lung implantation.19
Fiducial markers are used to facilitate image guidance 
for radiotherapy in lung tumors or to aid in intraoperative 
nodule localization during minimally invasive surgery.1,2,20 
Percutaneous marker insertion into lung lesions was first 
reported in 2001,21 but this approach has been associated with 
a very high rate of complications, with reports suggesting 
pneumothorax rates from 13%22 to over 60%.7–9 Intercostal 
tube insertion to manage pneumothorax is required in 3% to 
44%.7,9,22,23 Complication rates after marker insertion seem 
consistent with reported pneumothorax/intercostal drain-
age rates after percutaneous lung biopsy.13,24 Significantly, a 
markedly higher rate of pneumothorax in patients undergo-
ing concurrent biopsy at the time of marker placement has 
been reported.7
Bronchoscopy offers an appealing alternative to per-
cutaneous fiducial marker insertion given its superior safety 
profile. As peripheral lung lesions, by definition, are beyond 
bronchoscopic vision, guidance systems must be utilized 
to ensure that accurate placement of markers is achieved. 
Bronchoscopic fiducial marker insertion was first reported in 
2002 using fluoroscopic guidance to achieve placement near 
to peripheral lung tumors3; however, no subsequent studies 
have describe this technique. This almost certainly is due to 
the limitations of fluoroscopic guidance, which are illustrated 
by the modest diagnostic yields associated with broncho-
scopic investigation of peripheral pulmonary lesions.25,26 Up 
to 65% of peripheral lung cancers may be radiographically 
invisible,27 and prospective studies have demonstrated that 
lung malignancies are not visible on CXR/fluoroscopy until 
an average size of 2.4 cm is reached.
Development of more advanced bronchoscopic guidance 
tools such as EBUS,28,29 VB,30 and electromagnetic navigation31 
has significantly improved the diagnostic accuracy of bron-
choscopy in the assessment of peripheral pulmonary lesions. 
EBUS is an excellent tool to guide fiducial marker placement 
due to the ability to precisely locate the position of a tumor 
within the lung; up to 85% of malignant lesions may be located 
using EBUS,32,33 with the success rate of localization exceed-
ing 90% for lesions within 50 mm of the pulmonary hilum, and 
exceeding 80% for lesion greater than 10 mm diameter.33
Reports of VB-guided34 and ENB-directed5,10,11 marker 
placement have been published. Only one prior study has 
described the use of EBUS to guide marker placement.12 As we 
did, these authors used ENB to support bronchoscopic place-
ment in cases where EBUS was unable to locate the lesion. 
Their rate of EBUS-localization (72%) was slightly inferior 
to ours (81%), which may reflect the added value of VB in 
successful lesion localization.14 In addition, no reports to date 
have examined the geometric relationship between inserted 
markers and target lesions. Our study is therefore the first to 
our knowledge to utilize VB in association with EBUS to aid 
fiducial marker placement, and the first to describe the geo-
metric proximity between inserted markers and target tumors.
Our findings suggest that EBUS is the ideal modality to 
guide marker placement as it is able to achieve and confirm an 
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intimate relationship with the tumors during the procedure—
all EBUS-located lesions had marker placed either within or 
in contact with the lesion. Close placement to target lesions 
is desirable as intra- and interfractional variations in geomet-
ric relationship between lung tumors and inserted markers is 
minimized by close positioning of markers and is abolished 
entirely by placement within tumors.35 Misalignment during 
respiration is greater in cases where markers are placed at dis-
tances from the tumor greater than 2.5 cm.36
Whereas EBUS may be considered to be a localization 
tool, ENB should be considered a navigation tool. Previous 
studies have suggested that ENB may achieve successful 
localization in just 18% of peripheral lesions not detected 
by EBUS alone.37 This is evident in the significantly greater 
marker–lesion distances reported by authors using ENB guid-
ance without EBUS localization of the lesion.11 Our results 
confirm this as, in contrast to EBUS-guided markers (where 
all markers were successfully placed within target lesions), 
cases where marker placement was ENB-directed were placed 
a mean 12 mm from the lesion. The bronchoscope and the stiff 
EWC can cause significant displacement of the bronchial tree 
and lung targets.38 This can result in significant discrepancy 
FIGURE 2.  Postprocedure (A) 
CXR and (B) planning CT, demon-
strating successful implantation of 
fiducial marker within target lesion 
after EBUS localization of periph-
eral lung tumor. CT, computed 
tomography; CXR, chest x-ray; 
EBUS, endobronchial ultrasound.
FIGURE 3. A, Fluoroscopic imag-
ing demonstrating placement of 
fiducial marker targeting the (B) 
right mid-zone tumor seen on 
CT chest. C, CXR demonstrates 
apparent inferior migration of 
marker to lung base, confirmed 
on (D) postimplantation planning 
CT. CT, computed tomography; 
CXR, chest x-ray.
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between the passive position of pulmonary lesions (as mea-
sured during diagnostic CT) and their intraprocedural posi-
tion. This is illustrated by the 24 mm discrepancy observed 
in lesion 12 between intraprocedural AFTRE (a “virtual” 
measurement) and the final CT-demonstrated postprocedure 
marker–lesion distance, and by Supplementary Video file 1 
(Supplemental Digital Content 1, http://links.lww.com/JTO/
A730), which demonstrates the marked transient distortion 
that may result from either deliberate or inadvertent broncho-
scope manipulation. Perhaps reassuringly, the remaining four 
procedures all had variations of 4 mm or less between AFTRE 
and actual postprocedure marker–lesion distance.
The observed overall rate of marker migration (11.7%) 
was consistent with previously published data on both bron-
choscopically inserted5,12 and percutaneously inserted8,39,40 
markers. However, when analyzed by marker type, a signifi-
cant difference in stability was observed. No migration was 
observed among the nine dumbbell-shaped two-band markers, 
whereas the smaller linear markers experienced a high rate of 
early migration (25%). Migration occurred between 1 and 10 
days postinsertion, consistent with both clinical34 and histo-
pathologic41 studies after fiducial insertion.
Migration of lung fiducials may be a significant safety 
concern.42,43 Percutaneously inserted coils have previously been 
suggested to have a lower rate of migration than seed markers 
due to their ridged surface.23 Schroeder et al. reported a high 
rate of migration of bronchoscopically inserted linear mark-
ers, though the authors observed stability of 99% of coil spring 
markers sited bronchoscopically.10 We conclude from our 
findings, and from previous reports, that geometry of broncho-
scopically inserted lung fiducials is important in their stability.
Future Directions
Future developments are required to achieve improve-
ments in marker stability. Higher stability rates could allow 
lesions to be marked with a single marker, potentially reduc-
ing costs. High rates of marker migration3,42 and potential 
major complications of this42 have led to abandonment of 
solid markers into central airway malignancies. Even new 
technologies such as implantable transponders, used in pre-
clinical/phase I studies to allow electromagnetic tracking of 
tumors,44,45 have demonstrated significant challenges regard-
ing transponder stability within the lung.44,45
Alternative marker types to gold markers may be attrac-
tive. Submucosal injectable markers have been described,46 
and such formulations require further research to examine 
their utility.
Studies are required to establish the optimal marker 
size and geometry and the geographic relationship between 
fiducial and tumor. Increased marker size affords easier vis-
ibility during in-treatment imaging and placement within the 
tumor may most accurately allow real-time tumor tracking. It 
remains to be established that such enhancements to tumor 
tracking do not come at the cost of visualization during radio-
therapy planning studies.
CONCLUSION
Fiducial marker placement can be easily and safely 
performed bronchoscopically, including at the time of diag-
nostic bronchoscopy. Marker geometry appears important in 
stability of bronchoscopically inserted fiducials. Use of radial 
EBUS allows confirmation of marker placement within the 
tumor at the time of placement. In lesions not accessible 
to EBUS, ENB allows marker placement within acceptable 
proximity of the lesion. Future studies are required to confirm 
the optimal marker size, geometry and spatial relationship 
with the target lesion.
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